THE PHARMACOKINETICS AND SAFETY OF MOMELOTINIB IN SUBJECTS WITH MODERATE OR SEVERE RENAL IMPAIRMENT.

被引：0

作者：

Xin, Y. ^{[1
]}

Collins, H. ^{[1
]}

Cheng, F. ^{[1
]}

Kwan, E. ^{[1
]}

Ramanathan, S. ^{[1
]}

Silverman, J. A. ^{[1
]}

机构：

[1] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2016年 / 99卷

关键词：

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

PII-049

引用

页码：S87 / S88

页数：2

共 50 条

[41] Pharmacokinetics and pharmacodynamics of tonapofylline in subjects with severe renal impairment and in elderly subjects [J].

Li, Z. ;

TenHoor, C. ;

Marbury, T. ;

Swan, S. ;

Zhu, Y. ;

Ticho, B. .

INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2011, 49 (09) :563-570

[42] Pharmacokinetics and safety of telithromycin after single and multiple doses in patients with renal impairment. [J].

Shi, J ;

Montay, G ;

Chapel, S ;

Hardy, P ;

Barrett, J ;

Sack, M ;

Marbury, T ;

Swan, S ;

Vargas, R ;

Leclerc, V ;

Leroy, B ;

Bhargava, V .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (02) :P35-P35

[43] Pharmacokinetics of eslicarbazepine acetate in patients with renal impairment. [J].

Almeida, Luis ;

Potgieter, J. Henk ;

Maia, Joana ;

Soares-da-Silva, P. .

JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (09) :1193-1193

[44] EFFECT OF FIMASARTAN ON PHARMACOKINETICS IN PATIENTS WITH RENAL IMPAIRMENT. [J].

Kim, S. ;

Shin, D. ;

Kim, Y. S. ;

Cho, S. H. ;

Jang, I. J. ;

Lee, H. ;

Yu, K. S. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 :S72-S72

[45] Bucindolol (B) single dose pharmacokinetics (PK) in subjects with varying degrees of renal impairment. [J].

Ogunremi, A ;

Swan, S ;

Gehr, T ;

Sica, D ;

Sellers, J ;

Roberge, P ;

Ward, D .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 67 (02) :158-158

[46] Pharmacokinetics of oral maribavir, a novel anti-cytomegalovirus agent, in subjects with renal impairment. [J].

Swan, Suzanne ;

Smith, William ;

Marbury, Thomas ;

Schumacher, Mary ;

Dougherty, Carolyn ;

Mico, Bruce ;

Villano, Stephen .

BLOOD, 2006, 108 (11) :810A-811A

[47] PHARMACOKINETICS OF CEFODIZIME IN ELDERLY PATIENTS WITH MODERATE OR SEVERE RENAL IMPAIRMENT [J].

VEYSSIER, P ;

DEVILLERS, A ;

DOMART, Y ;

FOURTILLAN, JB ;

BRYSKIER, A ;

PROCYK, T .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1990, 26 :77-81

[48] Pharmacokinetics, Safety, and Tolerability of Tanimilast Following Single Administrations in Subjects With Mild, Moderate, and Severe Hepatic Impairment [J].

Emirova, A. ;

Piccino, A. ;

Rizzo, E. ;

Pittelli, M. ;

Bellatti, P. ;

Rostello, C. .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209

[49] PHARMACOKINETICS AND SAFETY OF TENOFOVIR ALAFENAMIDE IN SUBJECTS WITH SEVERE HEPATIC IMPAIRMENT [J].

Custodio, J. M. ;

Ma, G. ;

Cuvin, J. ;

Ting, L. ;

Flaherty, J. ;

Zack, J. Z. .

JOURNAL OF HEPATOLOGY, 2016, 64 :S594-S595

[50] FTY720 pharmacokinetics in mild to moderate hepatic impairment. [J].

Kovarik, JM ;

Schmouder, RL ;

Serra, D ;

Wang, Y ;

Lasseter, K .

AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 :473-473

← 1 2 3 4 5 →